Understand enclomiphene research in selected men with low testosterone, distinguish biomarkers from clinical benefit, and read ENCLOMID 25 labeling cautiously.
Enclomiphene is a SERM and the trans-isomer of clomiphene. Research in selected men with hypogonadism does not establish the efficacy or quality of the pictured SA ENCLOMID 25 product. [E1][E2]
1. Separate substance names from product labels
Enclomiphene identifies a substance; ENCLOMID 25 identifies wording on the supplied image. Its relationship to clomiphene does not establish universal interchangeability. A SERM mechanism is not proof of every proposed benefit. [E1]
2. What the human studies measured
Two phase 3 studies followed overweight men aged 18–60 with secondary hypogonadism for 16 weeks. Testosterone/LH/FSH increased and sperm concentration was maintained during the study. These endpoints do not establish pregnancy, live birth or training benefits. [E2]
Earlier phase 2 research also assessed hormonal and semen outcomes. These measurements should not be relabeled as guaranteed fertility or symptom improvement. [E4]
| Question | Evidence | Finding | Limitation |
|---|---|---|---|
| Hormone changes | Randomized studies in selected men | Hormonal changes observed | Not every population or symptom[E2] |
| Fertility/long-term outcomes | Reviewed studies focus on hormones/semen | Not established here | Sperm counts are not pregnancy/live birth[E4] |
| ENCLOMID 25 quality | Label image | NOT VERIFIED | No bottle/batch-specific proof |
3. Clinical benefit and regulatory context
EMA's EnCyzix assessment identified missing symptom-benefit evidence despite hormone changes, alongside venous-thromboembolism concerns. EU marketing authorization was refused on 6 April 2018. This is a dated, product-specific decision, not a complete current worldwide registration assessment. [E3]
4. An illustration, not product certification
The image displays SA Anabolic, ENCLOMID 25, Enclomiphene Citrate USP and 25 mg. It does not establish contents, potency, purity, authenticity or Thai registration. Printed USP wording is not a batch test.
This page supplies no dose, regimen, post-cycle protocol, price, purchase button or brand endorsement. Symptoms and treatment options require individual clinical assessment.
Frequently asked questions
Is enclomiphene testosterone?
No. It is a SERM related to clomiphene, not testosterone itself. [E1]
Do improved hormone results guarantee symptom improvement?
No. Clinical benefit needs separate evidence; EMA highlighted that gap for EnCyzix. [E3]
Do these studies prove improved fertility?
The reviewed endpoints concern hormones and semen, not demonstrated pregnancy or live-birth benefit. [E4]
Are 25 mg and USP a recommendation or certification?
No. They are visible label statements, not verified contents, quality or suitability for an individual.
Sources
Educational evidence context, not prescribing advice or product endorsement. Sources reviewed on 1 November 2026.